1. Início
  2. Publicações
  3. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • João Pedro Melo Marques Pinho Ferreira

    Autor

Participantes de fora da FMUP

  • Anker, SD
  • Butler, J
  • Usman, MS
  • Filippatos, G
  • Bocchi, E
  • Böhm, M
  • Brunner-La Rocca, HP
  • Choi, DJ
  • Chopra, V
  • Chuquiure, E
  • Giannetti, N
  • Gomez-Mesa, JE
  • Janssens, S
  • Januzzi, JL
  • González-Juanatey, JR
  • Merkely, B
  • Nicholls, SJ
  • Perrone, SV
  • Piña, IL
  • Ponikowski, P
  • Senni, M
  • Sim, D
  • Spinar, J
  • Squire, I
  • Taddei, S
  • Tsutsui, H
  • Verma, S
  • Vinereanu, D
  • Zhang, J
  • Iwata, T
  • Schnee, JM
  • Brueckmann, M
  • Pocock, SJ
  • Zannad, F

Unidades de investigação

Abstract

The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (= 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF = 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.420.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.

Dados da publicação

ISSN/ISSNe:
1546-170X, 1078-8956

Nature Medicine  Nature Publishing Group

Tipo:
Article
Páginas:
2512-2520
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 3

Citações Recebidas na Scopus: 16

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left; amino terminal pro brain natriuretic peptide; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; empagliflozin; enkephalinase inhibitor; ivabradine; mineralocorticoid antagonist; placebo; benzhydryl derivative; empagliflozin; glucoside; aged; all cause mortality; Article; atrial fibrillation; body mass; cardiovascular mortality; cardiovascular risk; chronic kidney failure; comparative study; controlled study; current smoker; diabetes mellitus; diastolic blood pressure; drug efficacy; ex-smoker; female; heart atrium flutter; heart failure with preserved ejection fraction; heart infarction; heart left ventricle ejection fraction; heart rate; hematocrit; human; hypertension; Kansas City Cardiomyopathy Questionnaire; major clinical study; male; never smoker; New York Heart A

Campos de estudo

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Citar a publicação

Partilhar a publicação